Uses the Hemotag device to track heart and vessel events in type 2 diabetes

Who can take part

• Adult patients older than 40 years of age
• Diagnosis of Type 2 Diabetes Mellitus (insulin dependent or non-insulin dependent) for at least 5 years
• Diagnosis of Cardiovascular Disease (Coronary Artery Disease, Cerebrovascular Disease, Peripheral Artery Disease, etc…) --OR--; Have one (1) of the following concomitant medical diagnoses:; Diabetic Retinopathy (proliferative or non-proliferative); Diabetic Nephropathy (eGFR \<60 mL/min/1.73m2 and/or urine albumin/creatinine ratio ≥30 mg/g); Diabetic Neuropathy; Elevated High-sensitivity C-reactive protein (hs-CRP) --AND--; Have a history of two (2) or more of the following:; Diagnosis of Hypertension for at least 6 months or more (treated or untreated); Hypercholesterolemia (LDL-C \>100 mg/dL); Obesity (Body Mass Index (BMI) ≥ 27 for men or ≥ 22 for women); History of Smoking
• Willingness to undergo HEMOTAG evaluation
• Willingness to undergo Standard of Care visits/assessments and NT-pro BNP lab evaluations
• Willingness to conduct at-home HEMOTAG evaluations at least three days per week within a 30-day time period after the completion of the Baseline Visit, after the 6 month visit and following discharge from any hospitalizations due to a cardiac events during the 12 month study period
• Willingness to receive and return shipping of the HEMOTAG KIT at each time point as required by the protocol
• Able to give informed consent

Who cannot take part

• Terminal condition with life expectancy less than 12 months as determined by investigator
• Illness/ Condition which may be aggravated or cause significant discomfort to the patient by the application of the HEMOTAG (skin issues, e.g. Intolerance to use of skin electrodes)
• Physical deformity in the chest area or lesion that may prevent proper HEMOTAG application or adjustment
• Participant enrolled in another interventional study (observational or registries are not excluded)
• Prisoners and wards of the state
• Impaired cognitive ability or any other state that may prevent full compliance with the study protocol, according to investigator\'s assessment
• Participants unable to provide informed, voluntary decision to participate in research study as determined by the investigator. (Exclude participants who necessitate the involvement of a legally authorized representative.)
• Inability to provide informed consent (Must speak English)
• Women who are pregnant or are planning to become pregnant during the study
• Women of childbearing potential who are unwilling or unable to comply with contraception measures